Codexis, Inc. Equity-NMS: CDXS

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$5.63

52W high :

$35.35

1Y :

-82.98%

5Y :

-32.83%

Shares O/S :

65.69 M

Market cap :

372.45 M

What is the share price of Codexis, Inc. today?

Codexis, Inc. (CDXS) share price as of October 12, 2022, is $5.24. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Codexis, Inc.?

Yes, Indian Investors can invest in the Codexis, Inc. (CDXS) Share by opening an international trading account with Angel One.

How can I purchase Codexis, Inc. shares in India?

Purchasing Codexis, Inc. (CDXS) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Codexis, Inc. (CDXS) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Codexis, Inc.?

Yes, you can purchase fractional shares of Codexis, Inc. (CDXS) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Codexis, Inc.?

The market capitalization of Codexis, Inc. on December 3, 2022, is $343.19 M.

In which sector Codexis, Inc. belongs?

Codexis, Inc. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Codexis, Inc. stocks?

In order to invest in Codexis, Inc. (CDXS) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and sells enzymes and other proteins. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The Company has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. It also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The Company is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).